

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

CHANGE OF DIRECTORS

The board of directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) is pleased to announce that Ms. Gao Shuping (“Ms. Gao”) has been appointed as Executive Director of the Company with effect from 29 July 2009; and Mr. Wang Zhizhong (“Mr. Wang”) has resigned as the Executive Director of the Company with effect from 29 July 2009 due to personal reasons. Mr. Wang has confirmed that he has no disagreement with the Board and there are no other matters that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) in relation to his resignation.

The details of Ms. Gao as required under Rule 13.51(2) of The Rules (the “Listing Rules”) Governing the Listing of Securities on the Stock Exchange are set out below.

Ms. Gao Shuping, aged 48, currently a director of New Orient Investments Limited, a direct wholly-owned subsidiary of the Company and a director and vice general manager of Shijiazhuang No. 4 Pharmaceutical Co., Ltd., an indirect wholly-owned subsidiary of the Company. Ms. Gao is responsible for implementation of infrastructure projects and land and property management. Ms. Gao joined Shijiazhuang No. 4 Pharmaceutical Factory in August 1982 and has been the chief officer of technology department and assistant chief engineer.

Ms. Gao has been the manager of quality department of Shijiazhuang Pharmaceutical Group Co., Ltd. from January 1998 to January 2002. Ms. Gao took up the post of vice general manager of Shijiazhuang No. 4 Pharmaceutical Co., Ltd. from January 2002 to December 2004. Afterwards, she served as a director and vice general manager of Shijiazhuang No. 4 Pharmaceutical Co., Ltd. from December 2004. Ms. Gao has been engaging in the quality management of pharmaceutical production and the technological transformation of pharmaceutical facilities for a long time, and has accumulated profound theoretical and practical experience. Ms. Gao graduated from Hebei Institute of Chemical Technology with a bachelor's degree majored in Chemical Technology. She is a senior engineer accredited by The Ministry of Personnel of the People's Republic of China.

Ms. Gao has entered into a service contract with the Company for a fixed term of three years commencing from 29 July 2009, subject to retirement and re-election provisions as set out in the Company's articles of association. Ms. Gao will be subject to election by shareholders at the next general meeting of the Company. Pursuant to the service contract, the annual director's emoluments of Ms. Gao is HK\$500,000 with discretionary bonus based on the Company's performance. The terms of appointment were approved by the Remuneration Committee of the Company and the Board with reference to Ms. Gao's qualification and experience, as well as the responsibilities to be undertaken. In addition, Ms. Gao is eligible to participate in the Company's share option scheme. Save as disclosed above, Ms. Gao does not have any relationships with any other directors, senior management or substantial shareholders (as defined in the Listing Rules), or controlling shareholders (as defined in the Listing Rules) of the Company.

Ms. Gao holds 6,000,000 share options. These options are related to the interests in shares of the Company granted by the Company to certain directors and senior management of the Group pursuant to the share option scheme on 7 August 2008. As at the date of this Announcement, all the options granted to Ms. Gao are outstanding. Save as disclosed above, as at the date of this announcement, Ms. Gao was not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Ms. Gao did not hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last 3 years. Save as disclosed above, there are no matters which are required to be brought to the attention of the shareholders of the Company, or to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Ms. Gao to the Board and thank Mr. Wang for his valuable contributions to the Company during his tenure of office as the Executive Director of the Company.

By order of the Board
Sze Wing Kin, Pierre
Company Secretary

Hong Kong, 29 July 2009

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Huang Chao, Mr. Xie Yunfeng, Ms. Sun Xinglai, Mr. Wang Xian Jun, Mr. Duan Wei, Ms. Zhang Guifu, Mr. Bao Leyuan and Ms. Gao Shuping as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.